Compare Adaptive Biotechnologies Corp (ADPT) vs GE Aerospace (GE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs GE Aerospace — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while GE Aerospace trades at $367.63 (market cap $381.89B). The key difference: GE Aerospace is far larger — about 94.5× Adaptive Biotechnologies Corp's market cap, and GE Aerospace pays a 0.51% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GE | |
|---|---|---|
Market Cap | $4.04B | $381.89B |
Sector | Health | Industrials |
52-Week High | $25.45 | $381.22 |
52-Week Low | $12.30 | $265.93 |
Enterprise Value | $4.10B | $391.70B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GE Aerospace (GE) trades at $368.06, down 0.55% with a bullish technical signal supported by strong earnings beats and robust order growth. The company shows impressive profitability with 48.79% ROE and 17.72% net margin, though valuation metrics appear elevated with a P/E of 43.24. Recent defense contract wins and commercial engine demand fuel positive sentiment, with analysts maintaining strong buy consensus.
GE presents growth potential through aerospace expansion and defense contracts, but faces risks from high debt levels and rich valuations. The $414.11 price target suggests 12.5% upside, supported by consistent earnings outperformance and strategic investments in manufacturing capacity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →
